NCT06330012招募中不适用
Spatial Transcriptomic Approach for Revealing the Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 50
- 试验地点
- 2
- 主要终点
- Spatial transcriptomic analysis
研究概览
简要总结
This study is the spatial transcriptomic approach for revealing the resistance mechanism of trastuzumab deruxtexan in HER2 positive breast cancer patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Screening
- 盲法
- None
入排标准
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •HER2 positive breast cancer
- •Stage IV disease
- •Treated with T-Dxd
- •Available FFPE samples
排除标准
- •TNBC breast cancer
- •Hormone receptor positive breast cancer
- •Non-available FFPE samples
- •Treated except T-Dxd
研究组 & 干预措施
Spatial transcriptomic approch
Experimental
Spatial transcriptomic approch for revealing the resistance mechanism of trastuzumab deruxtexan in HER2 positive breast cancer patients.
干预措施: GeoMx data analysis with clinical outcome (Diagnostic Test)
结局指标
主要结局
Spatial transcriptomic analysis
时间窗: Before chemotherapy, curative surgery
Protein expression and relationship protein-protein in HER2 positive breast cancer tumor cells and tumor microenvironment.
次要结局
未报告次要终点
研究者
JI-YEON, KIM
Professor
Samsung Medical Center
研究点 (2)
Loading locations...
相似试验
招募中
不适用
Spatially Transcriptomics Reveals Molecular Signatures in CRPSComplex Regional Pain SyndromesNCT05986461Seoul National University10
Unknown
不适用
Tyrosine Kinase Inhibitors In Metastatic Non Small Cell Lung CancerNon Small Cell Lung CancerNCT01163058Istituto Clinico Humanitas300
已完成
不适用
Study to Identify Mechanisms of Resistance to Standard Therapy in Patients With Metastatic Colorectal CancerColorectal CancerNCT00984048Jewish General Hospital160
已完成
不适用
Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer PatientsTriple Negative Breast CancerNCT01276899Jewish General Hospital80
已完成
不适用
A translational study on mechanism of resistance to PARP inhibitor in patients with breast cancer and gBRCA1/2 mutation (WJOG15321B)germline BRCA1/2 mutation-positive metastatic breast cancerJPRN-UMIN000046007West Japan Oncology Group60